These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
123 related articles for article (PubMed ID: 22975582)
1. RNA interference-mediated secretory clusterin gene silencing inhibits proliferation and promotes apoptosis of human non-small cell lung cancer cells. Yan Y; Luo K; Zhang H; Chai W Hepatogastroenterology; 2013; 60(121):70-5. PubMed ID: 22975582 [TBL] [Abstract][Full Text] [Related]
2. Silencing of secretory clusterin sensitizes NSCLC cells to V-ATPase inhibitors by downregulating survivin. Kim YS; Jin HO; Hong SE; Song JY; Hwang CS; Park IC Biochem Biophys Res Commun; 2018 Jan; 495(2):2004-2009. PubMed ID: 29253572 [TBL] [Abstract][Full Text] [Related]
3. IGF-1 activates the P13K/AKT signaling pathway via upregulation of secretory clusterin. Ma X; Bai Y Mol Med Rep; 2012 Dec; 6(6):1433-7. PubMed ID: 23027041 [TBL] [Abstract][Full Text] [Related]
4. Clusterin silencing inhibits proliferation and reduces invasion in human laryngeal squamous carcinoma cells. Wang Q; Cao W; Su Q; Liu Z; Zhang L World J Surg Oncol; 2014 Apr; 12():124. PubMed ID: 24767179 [TBL] [Abstract][Full Text] [Related]
5. Secreted clusterin gene silencing enhances chemosensitivity of a549 cells to cisplatin through AKT and ERK1/2 pathways in vitro. Zhang B; Zhang K; Liu Z; Hao F; Wang M; Li X; Yin Z; Liang H Cell Physiol Biochem; 2014; 33(4):1162-75. PubMed ID: 24751980 [TBL] [Abstract][Full Text] [Related]
6. Small interfering RNA targeted to secretory clusterin blocks tumor growth, motility, and invasion in breast cancer. Niu Z; Li X; Hu B; Li R; Wang L; Wu L; Wang X Acta Biochim Biophys Sin (Shanghai); 2012 Dec; 44(12):991-8. PubMed ID: 23099883 [TBL] [Abstract][Full Text] [Related]
7. siRNA-directed clusterin silencing promotes cisplatin antitumor activity in human non-small cell lung cancer xenografts in immunodeficient mice. Zhang B; Liu ZM; Hao FG; Wang M Eur Rev Med Pharmacol Sci; 2014 Jun; 18(11):1595-601. PubMed ID: 24943969 [TBL] [Abstract][Full Text] [Related]
8. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer. Zhou Y; Li S; Li J; Wang D; Li Q Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819 [TBL] [Abstract][Full Text] [Related]
9. Clusterin confers resistance to TNF-alpha-induced apoptosis in breast cancer cells through NF-kappaB activation and Bcl-2 overexpression. Wang Y; Wang X; Zhao H; Liang B; Du Q J Chemother; 2012 Dec; 24(6):348-57. PubMed ID: 23174100 [TBL] [Abstract][Full Text] [Related]
10. Secretory clusterin promotes oral cancer cell survival via inhibiting apoptosis by activation of autophagy in AMPK/mTOR/ULK1 dependent pathway. Naik PP; Mukhopadhyay S; Praharaj PP; Bhol CS; Panigrahi DP; Mahapatra KK; Patra S; Saha S; Panda AK; Panda K; Paul S; Aich P; Patra SK; Bhutia SK Life Sci; 2021 Jan; 264():118722. PubMed ID: 33160989 [TBL] [Abstract][Full Text] [Related]
11. Secretory clusterin promotes hepatocellular carcinoma progression by facilitating cancer stem cell properties via AKT/GSK-3β/β-catenin axis. Zheng W; Yao M; Wu M; Yang J; Yao D; Wang L J Transl Med; 2020 Feb; 18(1):81. PubMed ID: 32059741 [TBL] [Abstract][Full Text] [Related]
12. LncRNA HULC promotes non-small cell lung cancer cell proliferation and inhibits the apoptosis by up-regulating sphingosine kinase 1 (SPHK1) and its downstream PI3K/Akt pathway. Liu L; Zhou XY; Zhang JQ; Wang GG; He J; Chen YY; Huang C; Li L; Li SQ Eur Rev Med Pharmacol Sci; 2018 Dec; 22(24):8722-8730. PubMed ID: 30575912 [TBL] [Abstract][Full Text] [Related]
13. Induction of clusterin by AKT--role in cytoprotection against docetaxel in prostate tumor cells. Zhong B; Sallman DA; Gilvary DL; Pernazza D; Sahakian E; Fritz D; Cheng JQ; Trougakos I; Wei S; Djeu JY Mol Cancer Ther; 2010 Jun; 9(6):1831-41. PubMed ID: 20501799 [TBL] [Abstract][Full Text] [Related]
14. Clusterin, a Novel DEC1 Target, Modulates DNA Damage-Mediated Cell Death. Ming X; Bao C; Hong T; Yang Y; Chen X; Jung YS; Qian Y Mol Cancer Res; 2018 Nov; 16(11):1641-1651. PubMed ID: 30002194 [TBL] [Abstract][Full Text] [Related]
15. Clusterin modulates transdifferentiation of non-small-cell lung cancer. Jin R; Chen X; Han D; Luo X; Li H BMC Cancer; 2017 Sep; 17(1):661. PubMed ID: 28954633 [TBL] [Abstract][Full Text] [Related]
16. Effect of miR-21 on Apoptosis in Lung Cancer Cell Through Inhibiting the PI3K/ Akt/NF-κB Signaling Pathway in Vitro and in Vivo. Zhou B; Wang D; Sun G; Mei F; Cui Y; Xu H Cell Physiol Biochem; 2018; 46(3):999-1008. PubMed ID: 29669316 [TBL] [Abstract][Full Text] [Related]
17. Secretory clusterin contributes to oxaliplatin resistance by activating Akt pathway in hepatocellular carcinoma. Xiu P; Dong X; Dong X; Xu Z; Zhu H; Liu F; Wei Z; Zhai B; Kanwar JR; Jiang H; Li J; Sun X Cancer Sci; 2013 Mar; 104(3):375-82. PubMed ID: 23279642 [TBL] [Abstract][Full Text] [Related]
18. MiR-30a suppresses non-small cell lung cancer progression through AKT signaling pathway by targeting IGF1R. Wen XP; Ma HL; Zhao LY; Zhang W; Dang CX Cell Mol Biol (Noisy-le-grand); 2015 May; 61(2):78-85. PubMed ID: 26025408 [TBL] [Abstract][Full Text] [Related]
19. RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways. Feng Y; Hu J; Ma J; Feng K; Zhang X; Yang S; Wang W; Zhang J; Zhang Y Eur J Cancer; 2011 Oct; 47(15):2353-63. PubMed ID: 21680174 [TBL] [Abstract][Full Text] [Related]
20. MKP1 repression is required for the chemosensitizing effects of NF-kappaB and PI3K inhibitors to cisplatin in non-small cell lung cancer. Cortes-Sempere M; Chattopadhyay S; Rovira A; Rodriguez-Fanjul V; Belda-Iniesta C; Tapia M; Cejas P; Machado-Pinilla R; Manguan-García C; Sánchez-Pérez I; Nistal M; Moratilla C; de Castro-Carpeño J; Gonzalez-Barón M; Albanell J; Perona R Cancer Lett; 2009 Dec; 286(2):206-16. PubMed ID: 19553005 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]